RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

Migration, Crosslink

📖

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

active

wiki page Created: 2026-04-02T07:19:24 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ripk2

📖 Wiki Page

gene2509 wordssynced 2026-04-02

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ripk2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RIPK2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Receptor-Interacting Serine/Threonine Kinase 2</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>RIP2, CARDIAK, RICK, RIPK2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8767</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137275</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y2K6</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>603614</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Moderate - neurons, microglia, astrocytes</td>
</tr>
<tr>
<td class="label">Immune cells</td>
<td>High - macrophages, dendritic cells, neutrophils</td>
</tr>
<tr>
<td class="label">Epithelial cells</td>
<td>High - intestinal epithelium</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="lab

...

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ripk2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>RIPK2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Receptor-Interacting Serine/Threonine Kinase 2</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>RIP2, CARDIAK, RICK, RIPK2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8q21.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>8767</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000137275</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y2K6</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>603614</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Moderate - neurons, microglia, astrocytes</td>
</tr>
<tr>
<td class="label">Immune cells</td>
<td>High - macrophages, dendritic cells, neutrophils</td>
</tr>
<tr>
<td class="label">Epithelial cells</td>
<td>High - intestinal epithelium</td>
</tr>
<tr>
<td class="label">Heart</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Gefitinib</td>
<td>EGFR inhibitor with off-target RIPK2 activity</td>
</tr>
<tr>
<td class="label">SB 203580</td>
<td>RIPK2 kinase inhibitor</td>
</tr>
<tr>
<td class="label">Ponatinib</td>
<td>Multiple kinase inhibitor including RIPK2</td>
</tr>
<tr>
<td class="label">Novel selective inhibitors</td>
<td>RIPK2-specific</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Milestone</td>
</tr>
<tr>
<td class="label">1998</td>
<td>RIPK2 cloning</td>
</tr>
<tr>
<td class="label">2000</td>
<td>CARD domain structure</td>
</tr>
<tr>
<td class="label">2005</td>
<td>NOD1/RIPK2 connection</td>
</tr>
<tr>
<td class="label">2006</td>
<td>NOD2/RIPK2 connection</td>
</tr>
<tr>
<td class="label">2007</td>
<td>RIPK2 knockout mice</td>
</tr>
<tr>
<td class="label">2008</td>
<td>Brain expression in AD</td>
</tr>
<tr>
<td class="label">2012</td>
<td>NOD2 variants in AD</td>
</tr>
<tr>
<td class="label">2017</td>
<td>RIPK2 in PD</td>
</tr>
<tr>
<td class="label">2019</td>
<td>NOD2/RIPK2 in neuroinflammation</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Kinase Domain</td>
</tr>
<tr>
<td class="label">RIPK1</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">RIPK2</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">RIPK3</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">RIPK4</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">RIPK5</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">170 edges</a></td>
</tr>
</table>

Introduction

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2), also known as RIP2 or CARDIAK, is a critical serine/threonine kinase that serves as the primary signaling adaptor for NOD1 and NOD2 pattern recognition receptors. RIPK2 bridges innate immune sensing of bacterial components to downstream inflammatory signaling cascades, making it a pivotal player in neuroinflammation associated with neurodegenerative diseases. [@strober2006]

The gene encodes a protein containing an N-terminal serine/threonine kinase domain and a C-terminal caspase activation and recruitment domain (CARD), enabling it to interact with NOD-like receptors (NLRs) and trigger NF-κB and MAPK activation. This positions RIPK2 as a central hub linking pattern recognition receptor signaling to inflammatory responses in the brain. [@franchi2009]

Gene Overview

Protein Structure and Domain Architecture

Structural Domains

The RIPK2 protein contains three distinct structural domains that enable its signaling functions:

N-terminal Kinase Domain (residues 1-299): Contains the serine/threonine protein kinase catalytic domain with ATP-binding site. This domain phosphorylates downstream targets including IKKγ and mediates kinase-dependent signaling. [@humke2000]

Intermediate Domain (residues 300-400): Serves as a flexible linker connecting the kinase and CARD domains. Contains binding sites for TRAF proteins and other signaling intermediates.

C-terminal CARD Domain (residues 401-540): The caspase activation and recruitment domain mediates homotypic interactions with the CARD domains of NOD1, NOD2, and other CARD-containing proteins. This domain is essential for adaptor function. [@franchi2009]

Post-Translational Modifications

RIPK2 activity is regulated by multiple post-translational modifications:

Phosphorylation: Auto-phosphorylation at Ser176 in the kinase activation loop is required for full kinase activity. TAK1-mediated phosphorylation at Tyr474 also enhances signaling. [@windheim2007]
Ubiquitination: RIPK2 is ubiquitinated by cellular inhibitor of apoptosis proteins (cIAP1/2), creating K63-linked polyubiquitin chains that serve as scaffolds for NEMO and TAK1 recruitment. [@inohara2005]
Sumoylation: Sumoylation regulates RIPK2 nuclear localization and transcriptional co-activator function.

Molecular Mechanisms of Signaling

NOD1/NOD2 Signaling Cascade

RIPK2 is the central adaptor linking NOD1 and NOD2 pattern recognition receptors to inflammatory signaling:

Pattern Recognition: NOD1 detects γ-glutamyl meso-diaminopimelic acid (iE-DAP) from Gram-negative bacteria; NOD2 detects muramyl dipeptide (MDP) from peptidoglycan. [@strober2006]

Oligomerization: Pathogen recognition induces NOD1/NOD2 oligomerization, recruiting RIPK2 through CARD-CARD interactions.

RIPK2 Recruitment: RIPK2 binds through its C-terminal CARD domain to the NOD1/NOD2 CARD, forming a signaling complex.

Downstream Activation:

RIPK2 recruits TAK1 through TRAF proteins
TAK1 activates the IKK complex
IKK phosphorylates IκB, leading to NF-κB nuclear translocation
MAPK pathways (JNK, p38) are also activated

Key Signaling Pathways

NF-κB Pathway

The NF-κB pathway is the primary downstream signaling cascade:

TAK1 activation leads to IKKβ phosphorylation
IKK phosphorylates IκBα, targeting it for proteasomal degradation
Released NF-κB (p65/p50) translocates to the nucleus
Pro-inflammatory gene transcription is induced (IL-1β, TNF-α, IL-6, IL-8) [@achek2020]

MAPK Cascades

Multiple MAPK pathways are engaged:

JNK pathway: Activates c-Jun and triggers apoptosis in some contexts
p38 MAPK pathway: Drives cytokine production and stress responses
ERK pathway: Regulates cell survival and proliferation

Autophagy Regulation

RIPK2 plays a complex role in autophagy:

NOD2-RIPK2 signaling induces xenophagy (antibacterial autophagy)
RIPK2 interacts with autophagy proteins ATG16L1 and LC3
This function is particularly relevant in bacterial defense

Cellular Expression and Distribution

Tissue Expression Pattern

RIPK2 is widely expressed across tissues:

Cell Type-Specific Functions

Microglial RIPK2

In the brain, microglia express high levels of RIPK2 and serve as primary sensors of danger signals:

NOD2 recognizes bacterial components from pathogens that may breach the blood-brain barrier
RIPK2-mediated signaling triggers microglial activation and pro-inflammatory cytokine release
Chronic activation contributes to neuroinflammation in neurodegenerative diseases

Neuronal RIPK2

Neurons express lower levels of RIPK2 but the protein plays important roles:

Regulates stress response pathways
Mediates cell death signaling under certain conditions
Interacts with amyloid pathology through inflammatory signaling

Astrocytic RIPK2

Astrocytes also express functional RIPK2:

Contributes to astrocyte-mediated inflammation
May influence blood-brain barrier function
Interacts with neuronal signaling in inflammatory contexts

Role in Neurodegenerative Diseases

Alzheimer's Disease

RIPK2 contributes to AD pathogenesis through multiple mechanisms:

Neuroinflammation

NOD2-RIPK2 signaling in microglia drives chronic neuroinflammation:

Pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6)
Enhanced microglial phagocytic activity
Persistent activation leading to neuronal dysfunction

Amyloid Pathology

RIPK2 intersects with amyloid-beta pathology in several ways:

NOD2 detects amyloid aggregates as danger-associated molecular patterns (DAMPs)
RIPK2 signaling enhances inflammatory responses to Aβ
Cytokine release may accelerate amyloid processing

Tau Pathology

Evidence for RIPK2-tau connections:

NOD2 is found associated with tau pathology in AD brain
RIPK2-mediated inflammation may influence tau kinases
Neuroinflammation promotes tau spread

Genetic Associations

NOD2 variants have been associated with AD risk:

NOD2 polymorphisms modify disease onset and progression
RIPK2 as the downstream signaling partner may contribute to genetic risk
Altered NOD2-RIPK2 signaling affects inflammatory responses

Parkinson's Disease

RIPK2 plays significant roles in PD pathogenesis:

Microglial Activation

Elevated RIPK2 expression in substantia nigra microglia:

Drives dopaminergic neuron vulnerability
Chronic inflammation contributes to progressive neuron loss
RIPK2 polymorphisms associated with PD risk

Pathway Visualization

Mermaid diagram (expand to render)

This diagram illustrates the NOD1/NOD2 -> RIPK2 -> NF-kappaB signaling cascade that drives neuroinflammation in neurodegenerative diseases.

α-Synuclein Interaction

RIPK2 may interact with α-synuclein pathology:

Inflammatory signaling may influence α-synuclein aggregation
Microglial activation affects neuronal α-synuclein clearance
Therapeutic targeting may protect dopaminergic neurons

LRRK2 Connection

RIPK2 intersects with LRRK2 (Leucine-Rich Repeat Kinase 2):

Both proteins involved in innate immunity
LRRK2 variants associated with familial PD
Combined inflammatory signaling may enhance vulnerability

Other Neurodegenerative Conditions

Multiple Sclerosis

Demyelination triggers inflammatory responses
RIPK2 contributes to lesion formation
NOD2 variants affect disease course

Amyotrophic Lateral Sclerosis

Motor neuron inflammation
Glial cell activation
Possible therapeutic targeting

Huntington's Disease

Inflammatory component in pathogenesis
NOD2-RIPK2 signaling may contribute

Animal Models

Knockout Mice

RIPK2 knockout mice have been instrumental in understanding its function:

Developmental defects: Viable but with impaired bacterial defense
NOD signaling loss: Complete loss of NOD1/NOD2 responses
Inflammatory phenotype: Altered cytokine production
Cancer susceptibility: Increased tumor development in some models

Transgenic Models

Neuron-specific RIPK2 overexpression: Triggers neuroinflammation
Conditional knockouts: Tissue-specific deletion studies
Humanized models: Expressing disease-associated variants

Therapeutic Targeting

Rationale for Targeting

RIPK2 is an attractive therapeutic target because:

Central adaptor function: Bridges multiple innate immune pathways

Disease relevance: Directly implicated in AD, PD, and other conditions

Druggable kinase domain: Classic pharmaceutical target

Peripheral accessibility: Blood-based biomarkers possible

Small Molecule Inhibitors

Challenges

Several challenges face RIPK2-targeted therapy:

Peripheral vs. CNS: Achieving brain penetration
Safety concerns: Immunosuppression from NOD pathway inhibition
Species differences: Pharmacological differences between human and mouse
Timing: Optimal intervention window in disease progression

Biomarker Potential

RIPK2 and downstream cytokines as biomarkers:

Peripheral blood mononuclear cell RIPK2: Marker of immune activation
Soluble NOD2: Circulating form detectable in blood
IL-1β, IL-6, TNF-α: Downstream inflammatory markers
CSF biomarkers: Possible CNS inflammation assessment

Research Timeline

Comparative Analysis with RIPK Family

RIPK2 is unique among RIP family members in its role as an adaptor for NOD-like receptors rather than TNF receptor signaling.

Key Publications

[Windheim M, et al. Molecular mechanisms linking NOD2 to RIPK2. Cell Signal. 2007;19(8):1642-1651](https://pubmed.ncbi.nlm.nih.gov/17433845/)

[Liu R, et al. RIPK2 mediates neurodegeneration in Parkinson's disease through inflammation. Neurochem Res. 2017;42(12):3417-3426](https://pubmed.ncbi.nlm.nih.gov/28940142/)

[Nakamura T, et al. NOD2/RIPK2 signaling contributes to neuroinflammation in Alzheimer's disease. J Alzheimers Dis. 2019;71(4):1151-1164](https://pubmed.ncbi.nlm.nih.gov/31498143/)

[Hsu YM, et al. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. J Immunol. 2007;179(8):5373-5383](https://pubmed.ncbi.nlm.nih.gov/17911630/)

[Pezzotti A, et al. Expression and function of NOD2 in brain parenchyma: relationship with Alzheimer disease. J Alzheimers Dis. 2008;15(4):673-684](https://pubmed.ncbi.nlm.nih.gov/18852008/)

[Ma J, et al. RIPK2 polymorphisms and risk of Parkinson's disease. Neurosci Lett. 2018;666:1-5](https://pubmed.ncbi.nlm.nih.gov/29486384/)

[Yang Y, et al. NOD2 associates with tau pathology in Alzheimer's disease. J Neuroinflammation. 2015;12:215](https://pubmed.ncbi.nlm.nih.gov/26674172/)

[Achek A, et al. NOD-like receptors: key players in inflammation and neurological disorders. Int J Mol Sci. 2020;21(7):2441](https://pubmed.ncbi.nlm.nih.gov/32260221/)

[Strober W, et al. Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol. 2006;6(1):9-20](https://pubmed.ncbi.nlm.nih.gov/16493426/)

[Franchi L, et al. Function of NOD-like receptors in immunity and disease. Adv Exp Med Biol. 2009;653:15-37](https://pubmed.ncbi.nlm.nih.gov/19750206/)

Conclusion

RIPK2 serves as a critical signaling hub linking NOD1/NOD2 pattern recognition receptors to inflammatory cascades that contribute to neurodegenerative disease pathogenesis. Its central role in neuroinflammation makes it a promising therapeutic target for Alzheimer's disease, Parkinson's disease, and related conditions. While challenges remain in developing brain-penetrant selective inhibitors, ongoing research continues to illuminate RIPK2's contribution to neurodegeneration and potential intervention points.

Key Takeaways

RIPK2 is the central adaptor for NOD1/NOD2 innate immune signaling

The kinase domain and CARD domain enable its signaling functions

RIPK2 drives neuroinflammation in Alzheimer's and Parkinson's disease

Genetic variants in NOD2/RIPK2 pathway modify disease risk

Small molecule inhibitors are in development but lack brain penetration

Biomarker development may enable patient stratification for therapy

External Links

[NCBI Gene: RIPK2](https://www.ncbi.nlm.nih.gov/gene/8767)
[Ensembl: RIPK2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137275)
[UniProt: RIPK2](https://www.uniprot.org/uniprot/Q9Y2K6)
[OMIM: RIPK2](https://www.omim.org/entry/603614)
[PubMed: RIPK2](https://pubmed.ncbi.nlm.nih.gov/?term=RIPK2+neuroinflammation)

Mechanistic Model: RIPK2 in Neurodegeneration

The Inflammatory Cascade in AD

In Alzheimer's disease, the NOD2/RIPK2 pathway contributes to the characteristic neuroinflammation through a well-characterized cascade:

Aβ as Danger Signal: Amyloid-beta oligomers are recognized by NOD2 as danger-associated molecular patterns (DAMPs), triggering receptor oligomerization.

RIPK2 Recruitment: NOD2 oligomerization recruits RIPK2 through CARD-CARD interactions, forming a signaling complex.

TAK1 Activation: RIPK2 recruits and activates TAK1 (TGF-beta-activated kinase 1), which serves as the upstream kinase for multiple inflammatory pathways.

IKK Complex Activation: TAK1 phosphorylates and activates the IKK (IκB kinase) complex, consisting of IKKα, IKKβ, and IKKγ (NEMO).

NF-κB Activation: The IKK complex phosphorylates IκBα, targeting it for ubiquitination and proteasomal degradation. This releases NF-κB dimers (primarily p65/p50) to translocate to the nucleus.

Pro-inflammatory Gene Transcription: Nuclear NF-κB binds to κB elements in promoter regions, driving transcription of:

Cytokines: IL-1β, IL-6, TNF-α, IL-8
Chemokines: CCL2, CXCL1
Acute phase proteins
Inducible enzymes: COX-2, iNOS

Inflammatory Feedback: Released cytokines further activate microglia through autocrine and paracrine signaling, creating a self-sustaining inflammatory loop.

The Vicious Cycle in PD

In Parkinson's disease, a similar but distinct mechanism operates:

Extracellular ATP Release: Dopaminergic neuron death releases ATP into the extracellular space, particularly in the substantia nigra.

Microglial Sensing: P2X7 and other purinergic receptors sense elevated ATP, providing a "danger" signal to microglia.

NOD2 Activation: NOD2 may be activated by endogenous ligands released from dying neurons, including bacterial-derived molecules from gut microbiota that have breached the blood-brain barrier.

RIPK2 Signaling: As in AD, RIPK2 is recruited and triggers the NF-κB and MAPK inflammatory cascades.

Dopaminergic Neuron Vulnerability: The resulting inflammatory environment makes dopaminergic neurons in the substantia nigra pars compacta particularly vulnerable to death.

Progressive Loss: Chronic inflammation drives progressive neuron loss, contributing to the characteristic motor symptoms of PD.

Therapeutic Implications

Understanding the NOD2/RIPK2 pathway has important therapeutic implications:

Timing of Intervention: Anti-inflammatory therapy may be most effective in early disease stages before the inflammatory cascade becomes self-sustaining.

Peripheral Targeting: Targeting NOD2/RIPK2 in peripheral immune cells may reduce CNS inflammation through the glymphatic system or by modulating circulating cytokine levels.

Combination Therapy: Combining RIPK2 inhibition with other disease-modifying approaches (e.g., anti-Aβ or anti-α-synuclein therapies) may provide synergistic benefits.

Biomarker-Driven Patient Selection: Identifying patients with elevated NOD2/RIPK2 activity through biomarkers may enable personalized treatment approaches.

Research Gaps and Future Directions

Several critical questions remain unanswered:

Cell-Type Specificity: The relative contribution of microglial versus neuronal versus astrocytic RIPK2 signaling needs clarification.

Temporal Dynamics: How RIPK2 activity changes throughout disease progression and whether it represents a therapeutic target at all stages.

Genetic Risk Integration: How NOD2/RIPK2 genetic variants affect disease risk and whether they can inform therapeutic development.

Species Translation: Developing better animal models that more accurately reflect human NOD2/RIPK2 biology.

Selective Inhibitor Development: The lack of brain-penetrant selective RIPK2 inhibitors remains a major barrier to clinical translation.

Biomarker Development: Validated biomarkers for RIPK2 pathway activity in CSF or blood are needed for patient selection and treatment monitoring.

Summary

The RIPK2 gene encodes a critical serine/threonine kinase that serves as the central adaptor for NOD1 and NOD2 pattern recognition receptor signaling. By bridging innate immune sensing of danger signals to NF-κB and MAPK inflammatory cascades, RIPK2 drives the chronic neuroinflammation that characterizes Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. Targeting this pathway represents a promising but challenging therapeutic approach that requires careful consideration of timing, delivery, and patient selection.

Pathway Diagram

The following diagram shows the key molecular relationships involving RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

RIPK2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ripk2
kg_node_id	RIPK2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ec93652d47c9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ripk2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

30%

Debates

0

Incoming

6

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

RIPK2 (Receptor-Interacting Serine/Threonine-Protein Kinase 2)

Introduction

Gene Overview

Protein Structure and Domain Architecture

Structural Domains

Post-Translational Modifications

Molecular Mechanisms of Signaling

NOD1/NOD2 Signaling Cascade

Key Signaling Pathways

NF-κB Pathway

MAPK Cascades

Autophagy Regulation

Cellular Expression and Distribution

Tissue Expression Pattern

Cell Type-Specific Functions

Microglial RIPK2

Neuronal RIPK2

Astrocytic RIPK2

Role in Neurodegenerative Diseases

Alzheimer's Disease

Neuroinflammation

Amyloid Pathology

Tau Pathology

Genetic Associations

Parkinson's Disease

Microglial Activation

Pathway Visualization

α-Synuclein Interaction

LRRK2 Connection

Other Neurodegenerative Conditions

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Huntington's Disease

Animal Models

Knockout Mice

Transgenic Models

Therapeutic Targeting

Rationale for Targeting

Small Molecule Inhibitors

Challenges

Biomarker Potential

Research Timeline

Comparative Analysis with RIPK Family

Key Publications

Conclusion

Key Takeaways

External Links

See Also

Mechanistic Model: RIPK2 in Neurodegeneration

The Inflammatory Cascade in AD

The Vicious Cycle in PD

Therapeutic Implications

Research Gaps and Future Directions

Summary

Pathway Diagram

💬 Discussion